Menu
Montecito
Pac Premier
Giving Guide
Loading...
You are here:  Home  >  'Kyprolis'  -  Page 3
Latest

European regulators approve Amgen cancer drug Kyprolis

By   /  Thursday, November 19th, 2015  /  Central Coast Health Watch, Latest news, Technology  /  Comments Off on European regulators approve Amgen cancer drug Kyprolis

Thousand Oaks-based Amgen scored another major victory Nov. 19. European regulators approved experimental drug Kyprolis on Thursday for patients who have received at least one prior treatment for multiple-myeloma. Kyprolis was the cornerstone of Amgen’s $10.4 billion buyout of Onyx Pharmaceuticals in 2013. Multiple-myeloma is a form of blood cancer that forms in plasma cells Read More →

Read More →
Latest

Amgen cancer drug Kyprolis to get expedited review from FDA

By   /  Friday, September 18th, 2015  /  Central Coast Health Watch, Latest news, Tri-County Public Companies  /  Comments Off on Amgen cancer drug Kyprolis to get expedited review from FDA

An experimental multiple myeloma treatment using Amgen’s Kyprolis will get an expedited review from the U.S. Food and Drug Administration. The FDA said it will use an expedited review process to review a multiple-myeloma treatment using Kyprolis and the genric drug dexamethasone. On July 23, Amgen submitted additional data to the FDA which compared this Read More →

Read More →
Latest

FDA approves Amgen’s Kyprolis

By   /  Friday, July 24th, 2015  /  Central Coast Health Watch, East Ventura County, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on FDA approves Amgen’s Kyprolis

The Food and Drug Administration approved Amgen’s Kyprolis for second-line treatments of multiple-myeloma on Friday. Thousand Oaks-based Amgen’s new treatment for multiple-myeloma could pay off big for the company now that the treatment can be accessed by more patients in the second line of treatments. Kyprolis was approved for third-line treatments in 2012. The FDA’s Read More →

Read More →
Latest

Amgen submits data on cancer drug Kyprolis to FDA

By   /  Thursday, July 23rd, 2015  /  Central Coast Health Watch, Latest news, Technology, Top Stories, Tri-County Public Companies  /  Comments Off on Amgen submits data on cancer drug Kyprolis to FDA

Thousand Oaks-based Amgen announced Thursday that it submitted data comparing its new multiple-myeloma drug against a rival to the Food and Drug Administration. Kyprolis is Amgen’s new treatment for multiple-myeloma, which is a form of blood cancer that forms in plasma cells and typically grows in bone marrow. The drug was approved for third-line treatments Read More →

Read More →
Latest
Premium Content

Amgen’s gamble on new cancer drug may pay off

By   /  Friday, July 17th, 2015  /  Central Coast Health Watch, Latest news, Technology, Top Stories  /  Comments Off on Amgen’s gamble on new cancer drug may pay off

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Page 3 of 3 1 2 3